Urologix, Inc. (ULGX) - 500 Beiträge pro Seite

[panik]

Profile:Urologix, Inc. engages in the design, development, manufacture, and marketing of medical devices for the treatment of benign prostatic hyperplasia (BPH). It markets its products under Targis and Prostatron names. BPH is a disease that causes adverse changes in urinary voiding patterns in men. The company offers nonsurgical and catheter-based therapies that use a proprietary cooled microwave technology. Urologix is based in Minneapolis, Minnesota.

http://www.urologix.com/

[panik]

[scopus]

[scopus]

Nur Insiderkäufe!
und profitabel!
das für ein biotechunternehmen!!

Purchase 2006-08-22 2006-08-23
10:19:57 UROLOGIX INC ULGX STARKS DANIEL J Director 10,000 $3.002 $30,017 30,000
Purchase 2006-08-21 2006-08-21
16:03:29 UROLOGIX INC ULGX EMERY SIDNEY W JR Director 8,000 $2.875 $23,000 20,236
Purchase 2006-06-06 2006-06-08
12:57:19 UROLOGIX INC ULGX EMERY SIDNEY W JR Director 2,000 $3.42 $6,840 12,236 Purchase 2006-05-17 2006-05-19
13:14:59 UROLOGIX INC ULGX EMERY SIDNEY W JR Director 936 $3.26 $3,051 10,236
Purchase 2006-05-15-
-2006-05-16 2006-05-17
17:18:12 UROLOGIX INC ULGX PARKS FRED B Chief Executive Officer
Director 16,085 $3.4 $54,689 93,135
Purchase 2006-05-03 2006-05-03
15:03:10 UROLOGIX INC ULGX EMERY SIDNEY W JR Director 3,000 $3.4 $10,200 9,300 Purchase 2006-02-01 2006-02-02
18:09:09 UROLOGIX INC ULGX EMERY SIDNEY W JR Director 5,500 $3.7 $20,350 6,300 Purchase 2005-11-25 2005-11-29
11:52:13 UROLOGIX INC ULGX EMERY SIDNEY W JR Director 500 $4.3 $2,150 800 Purchase 2005-11-03 2005-11-08
21:30:06 UROLOGIX INC ULGX JACKSON GUY C Director 5,000 $3.95 $19,750 5,000
Purchase 2005-05-12 2005-05-13
09:36:32 UROLOGIX INC ULGX PAULSON TODD Chief Financial Officer 4,000 $4.55 $18,200 8,549

[scopus]

neuer insiderkauf!

[scopus]

neuer insiderkauf!!!

[scopus]

so ULGX erwacht langsam

[scopus]

heute geht es weiter

[scopus]

Urologix to Present at the BMO Capital Markets Health Care Conference
Wednesday December 6, 10:27 am ET


MINNEAPOLIS--(BUSINESS WIRE)--Urologix®, Inc. (NASDAQ:ULGX - News) today announced that Fred B. Parks, Chairman and Chief Executive Officer, will present at the BMO Capital Markets Health Care Conference on Thursday, December 7, 2006 at 10:00 am ET. The conference is being held at the Millennium Broadway Hotel in New York City.


A live audio webcast of the presentation will be available to all interested parties through the "Investors" section of the Urologix website at www.urologix.com or directly accessed by the following link: http://www.bmocm.com/conferences/healthcare2006/webcast/defa…

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix' products include the CoolWave(TM), Targis® and Prostatron® control units and the Cooled ThermoCath®, Targis® and Prostaprobe® catheter families. All of Urologix' products utilize Cooled ThermoTherapy(TM) - targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.



Contact:
Urologix, Inc., Minneapolis
Fred B. Parks, Chairman and CEO, 763-475-1400
or
Elissa J. Lindsoe, CFO, 763-475-1400

--------------------------------------------------------------------------------
Source: Urologix, Inc.

[scopus]

volumen steigt!!!!

[scopus]

tageshöchstand geschlossen

[scopus]

keiner dabei?

[panik]

Urologix Reports Fiscal 2007 Second Quarter Results
Thursday January 25, 4:05 pm ET
Revenue was $6.0 Million, up 11% from First Quarter of Fiscal 2007; Cash and Cash Equivalents Grew to $12 Million


MINNEAPOLIS--(BUSINESS WIRE)--Urologix®, Inc. (NASDAQ:ULGX - News), today reported financial results for the fiscal 2007 second quarter ended December 31, 2006. Revenue for the second quarter was $6.0 million compared to $5.4 million reported in the first quarter of fiscal 2007 and $6.5 million in the second quarter of fiscal 2006. During the second quarter, average selling prices remained comparable to those in the prior quarter while catheter sales to direct accounts drove the 11 percent sequential improvement in overall revenue.
ADVERTISEMENT


Net income for the second quarter was $0.1 million, or $0.01 per diluted share, compared to a net loss of $0.5 million, or $0.04 per diluted share in the first quarter of fiscal 2007 and net income of $0.3 million, or $0.02 per diluted share, in the second quarter of fiscal 2006. For the six months ended December 31, 2006, revenue was $11.4 million compared to $12.7 million in the prior year period. The net loss for the six months ended December 31, 2006 was $0.4 million, or $0.03 per diluted share, compared to net income of $0.5 million, or $0.03 per diluted share, for the six months ended December 31, 2005.

"The second quarter rebound is encouraging," said Fred B. Parks, chairman and chief executive officer of Urologix, "Our return to profitability as well as the strengthening of our balance sheet are further validation that we have a healthy foundation. We want to maintain this momentum while broadening our product appeal to a greater patient population."

Gross profit for the second quarter of fiscal 2007 was $3.6 million, or 59 percent of revenue, a 4 percentage point improvement when compared to 55 percent of revenue in the first quarter of fiscal 2007 and an 8 percentage point decrease when compared to 67 percent of revenue in the same period last year. The majority of the sequential improvement in the gross profit rate was due to a shift in product mix. Further contributing to the sequential improvement, the Company experienced significant reductions in overtime and scrap as the Company made progress toward the resolution of the manufacturing issues that surfaced during the fourth quarter of fiscal 2006. Second quarter operating expenses totaled $3.5 million, compared to $3.7 million in the first quarter of fiscal 2007 and $4.0 million in the second quarter of fiscal 2006 as the Company continues to prudently manage its expenses.

Balances of cash and cash equivalents increased to $12.0 million at December 31, 2006 from $10.8 million at September 30, 2006, due primarily to improved cash collections driven by increased revenue and by increased emphasis on collecting aged accounts. Days sales outstanding improved to 63 from 70 days in the prior quarter.

"We are delighted with the cash and accounts receivable improvements made during our second quarter", said Elissa Lindsoe, chief financial officer of Urologix. "We will continue to remain focused on utilizing our assets wisely while spending appropriately in areas that will contribute to our future success".

Current Outlook

The Company believes that revenue in the third quarter of fiscal 2007 will improve modestly over that reported in the second quarter. Third quarter product development and selling expenses are expected to increase from those reported in the second quarter of fiscal 2007. The Company's management expects third quarter earnings before taxes to be positive.

Earnings Call Information

Urologix will host a conference call with the financial community to discuss fiscal 2007 second quarter results on Thursday, January 25, at 4:00 p.m. Central Time. A live webcast of the call will be available through the investor relations section of the Company's website at www.urologix.com, and available for replay approximately two hours after the completion of the call.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix' products include the CoolWave(TM), Targis® and Prostatron® control units and the Cooled ThermoCath®, Targis® and Prostaprobe® catheter families. All of Urologix' products utilize Cooled ThermoTherapy(TM) - targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include, for example, statements relating to second quarter fiscal year 2007 revenue and earnings, statements about the Company's plans and future performance, statements about the Company's ability to develop and market new products, including the Company-owned Cooled ThermoTherapy mobile service, and other statements that use such words as "may," "will," "expect," "believe" and "plan."

Actual results may vary significantly from those anticipated in these forward-looking statements due to risks and uncertainties, including the need to return to profitability and increase revenue; the rate of adoption of Cooled ThermoTherapy products, Urologix' sole products, by the medical community; approval by the FDA of the Company's products; product liability claims inherent in the testing, production, marketing and sale of medical devices; the ability of third-party suppliers to produce and supply products; the Company's ability to maintain product yields on a cost efficient basis; the impact of competitive treatments, products and pricing; the Company's ability to develop and market new products, including the Company-owned Cooled ThermoTherapy mobile service and the CoolWave control unit, and the Company's ability to generate revenue from new products; the development and effectiveness of the Company's sales organization and marketing efforts; developments in the reimbursement environment for the Company's products including the determination of reimbursement rates for Cooled ThermoTherapy (transurethral microwave thermotherapy); the Company's ability to successfully defend its intellectual property against infringement and the cost and expense associated with that effort; and other risks and uncertainties detailed from time to time in Urologix' filings with the Securities and Exchange Commission, including its most recently filed Annual Report on Form 10-K for the year ended June 30, 2006.

Urologix, Inc.
Condensed Statements of Operations
(Unaudited, in thousands, except per share data)

Three Months Ended Six Months Ended
December 31, December 31,

--------- --------- --------- ---------
2006 2005 2006 2005
--------- --------- --------- ---------

Sales $6,011 $6,535 $11,426 $12,692
Cost of goods sold 2,445 2,182 4,856 4,214
--------- --------- --------- ---------
Gross profit 3,566 4,353 6,570 8,478
--------- --------- --------- ---------

Costs and expenses:
Selling, general and
administrative 2,792 3,222 5,764 6,393
Research and development 639 785 1,255 1,581
Amortization of intangibles 71 41 142 82
--------- --------- --------- ---------
Total costs and expenses 3,502 4,048 7,161 8,056
--------- --------- --------- ---------

Operating earnings (loss) 64 305 (591) 422
Interest income 140 88 269 145
--------- --------- --------- ---------
Net earnings (loss) before
income taxes 204 393 (322) 567

Income tax expense 57 74 57 102
--------- --------- --------- ---------
Net earnings (loss) $147 $319 $(379) $465
========= ========= ========= =========

Net earnings (loss) per common
share--basic $0.01 $0.02 $(0.03) $0.03
========= ========= ========= =========

Net earnings (loss) per common
share--diluted $0.01 $0.02 $(0.03) $0.03
========= ========= ========= =========

Weighted average number of
shares used in basic per
share calculations 14,333 14,314 14,332 14,312
========= ========= ========= =========

Weighted average number of
shares used in diluted per
share calculations 14,335 14,356 14,332 14,376
========= ========= ========= =========

Urologix, Inc.
Condensed Balance Sheets
(Unaudited, in thousands)

December 31, June 30,
2006 2006
------------ ------------
Current Assets:
Cash, and cash equivalents $12,047 $11,054
Accounts receivable, net 4,227 5,234
Inventories 2,842 2,634
Deferred tax asset 943 992
Prepaids and other current assets 317 184
------------ ------------
Total current assets 20,376 20,098
------------ ------------

Property and equipment:
Machinery, equipment and furniture 12,072 11,562
Less accumulated depreciation (9,334) (8,665)
------------ ------------
Property and equipment, net 2,738 2,897
Other assets 1,119 1,288
Goodwill 10,193 10,193
Other intangible assets, net 6,698 7,090
Deferred tax asset, net 2,332 2,332
------------ ------------
Total assets $43,456 $43,898
============ ============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $1,033 $1,375
Accrued compensation 645 826
Deferred income 237 242
Other accrued expenses 704 729
------------ ------------
Total current liabilities 2,619 3,172
Deferred income 616 712
Other accrued expenses 11 34
------------ ------------
Total liabilities 3,246 3,918
------------ ------------

Shareholders' equity:
Common stock 143 143
Additional paid-in capital 112,059 111,450
Accumulated deficit (71,992) (71,613)
------------ ------------
Total shareholders' equity 40,210 39,980
------------ ------------
Total liabilities and shareholders'
equity $43,456 $43,898
============ ============



Contact:
Urologix, Inc.
Fred B. Parks, Chairman and CEO, 763-475-1400
or
Elissa J. Lindsoe, CFO, 763-475-1400

--------------------------------------------------------------------------------
Source: Urologix, Inc.

[50bager]

ULGX: Q3 EPS (5c) vs 3c Misses (2c) Est

Wednesday, May 09, 2007 08:42ET

QUARTER RESULTS
Urologix, Incorporated (ULGX) reported Q3 results ended March 2007. Q3 Revenues were $5.07M; -22.60% vs yr-ago; MISSING revenue consensus by -0.59%. Q3 EPS was (5c); -266.67% vs yr-ago; MISSING earnings consensus by -150.00%.

Q3 RESULTS Reported Year-Ago Y/Y Chg Estimate SURPRISE
---------- ------------ ------------ ---------- ------------ ----------
Revenues: $5.07M $6.55M -22.60% $5.10M -0.59%
---------- ------------ ------------ ---------- ------------ ----------
EPS: (5c) 3c -266.67% (2c) -150.00%
---------- ------------ ------------ ---------- ------------ ----------


ORIGINAL EARNINGS RELEASE
Consensus estimate data provided by Reuters.
Visit Knobias.com for more indepth earnings information.

[50bager]